Evaluation of respiratory complications in patients with X-linked and autosomal recessive agammaglobulinemia.


Journal

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718

Informations de publication

Date de publication:
05 2020
Historique:
received: 11 12 2019
revised: 23 01 2020
accepted: 24 01 2020
pubmed: 15 2 2020
medline: 7 2 2021
entrez: 15 2 2020
Statut: ppublish

Résumé

Congenital agammaglobulinemia is the first primary immunodeficiency disorder characterized by a defect in B lymphocyte development and subsequently decreased immunoglobulin levels. These patients are prone to suffer from recurrent infections mostly involving the respiratory tract. In this study, we aimed to describe in detail respiratory tract complications as the most prominent clinical feature among agammaglobulinemic patients. A total number of 115 patients were included. Demographic, clinical, and genetic data were collected from the patients' medical records. Among the available patients, pulmonary function tests (PFTs) and/or high-resolution computed tomography (HRCT) were performed. Respiratory tract complications (85.2%) especially pneumonia (62.6%) were the most prominent clinical features in our cohort. Among patients with abnormal PFT results (N = 19), a mixed respiratory pattern was observed in 36.8%. HRCT was carried out in 29 patients; Bhalla scoring-based evaluation of these patients indicated excellent (44.8%), followed by good (34.5%) and mild (20.7%) results. Bronchiectasis was found in 13 patients undergoing HRCT (44.8%). We found significant inverse correlations between the Bhalla score and incidence rate of pneumonia, as well as the presence of bronchiectasis. Patients with abnormal PFT results had statistically significant higher bronchiectasis frequency and lower Bhalla scores compared to those with normal results. Forty-one patients were deceased, and here, respiratory failure was the most common cause of death (45.5%). High prevalence of respiratory tract infections among agammaglobulinemic patients and subsequent progression to permanent lung damage highlights the importance of implementing respiratory evaluation as part of routine follow-up program of agammaglobulinemic patients. Physicians should be aware of this and regularly monitor the respiratory function of these patients to allow for timely diagnosis and treatment initiation aiming to improve patients' prognosis and quality of life.

Sections du résumé

BACKGROUND
Congenital agammaglobulinemia is the first primary immunodeficiency disorder characterized by a defect in B lymphocyte development and subsequently decreased immunoglobulin levels. These patients are prone to suffer from recurrent infections mostly involving the respiratory tract. In this study, we aimed to describe in detail respiratory tract complications as the most prominent clinical feature among agammaglobulinemic patients.
METHODS
A total number of 115 patients were included. Demographic, clinical, and genetic data were collected from the patients' medical records. Among the available patients, pulmonary function tests (PFTs) and/or high-resolution computed tomography (HRCT) were performed.
RESULTS
Respiratory tract complications (85.2%) especially pneumonia (62.6%) were the most prominent clinical features in our cohort. Among patients with abnormal PFT results (N = 19), a mixed respiratory pattern was observed in 36.8%. HRCT was carried out in 29 patients; Bhalla scoring-based evaluation of these patients indicated excellent (44.8%), followed by good (34.5%) and mild (20.7%) results. Bronchiectasis was found in 13 patients undergoing HRCT (44.8%). We found significant inverse correlations between the Bhalla score and incidence rate of pneumonia, as well as the presence of bronchiectasis. Patients with abnormal PFT results had statistically significant higher bronchiectasis frequency and lower Bhalla scores compared to those with normal results. Forty-one patients were deceased, and here, respiratory failure was the most common cause of death (45.5%).
CONCLUSION
High prevalence of respiratory tract infections among agammaglobulinemic patients and subsequent progression to permanent lung damage highlights the importance of implementing respiratory evaluation as part of routine follow-up program of agammaglobulinemic patients. Physicians should be aware of this and regularly monitor the respiratory function of these patients to allow for timely diagnosis and treatment initiation aiming to improve patients' prognosis and quality of life.

Identifiants

pubmed: 32058651
doi: 10.1111/pai.13228
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

405-417

Informations de copyright

© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Références

Azizi G, Yazdani R. Predominantly antibody deficiencies. Immunol Genet J. 2018;1(2):52-80.
Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat Rev Immunol. 2013;13(7):519-533.
Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722-728.
Cassidy JT, Nordby GL. Human serum immunoglobulin concentrations: prevalence of immunoglobulin deficiencies. J Allergy Clin Immunol. 1975;55(1):35-48.
Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol. 2000;19(2):183-204.
Ochs HD, Smith CI. X-linked agammaglobulinemia a clinical and molecular analysis. Medicine (Baltimore). 1996;75(6):287-299.
Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221-230.
Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279-290.
Abolhassani H, Parvaneh N, Rezaei N, Hammarstrom L, Aghamohammadi A. Genetic defects in B-cell development and their clinical consequences. J Investig Allergol Clin Immunol. 2014;24(1):6-22; quiz 22 p following 22.
Sawada A, Takihara Y, Kim JY, et al. A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. J Clin Investig. 2003;112(11):1707-1713.
Barmettler S, Otani IM, Minhas J, et al. Gastrointestinal manifestations in X-linked agammaglobulinemia. J Clin Immunol. 2017;37(3):287-294.
Suri D, Rawat A, Singh S. X-linked agammaglobulinemia. Indian J Pediatr. 2016;83(4):331-337.
Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE. Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract. 2016;4(6):1059-1065.
Chan HY, Yang YH, Yu HH, Chien YH, Chiang LL, Chiang BL. Clinical characteristics and outcomes of primary antibody deficiency: a 20-year follow-up study. J Formos Med Assoc. 2014;113(6):340-348.
Pac MM, Bernatowska EA, Kierkuś J, et al. Gastrointestinal disorders next to respiratory infections as leading symptoms of X-linked agammaglobulinemia in children - 34-year experience of a single center. Arch Med Sci. 2017;13(2):412-417.
Suri D, Rawat A, Singh S. X-linked agammaglobulinemia. Indian J Pediatr. 2016;83(4):331-337.
Shirmast P, Al-Hussieni Jasim Mohammad Rida K. Evaluating autoimmunity in patients with agammaglobulinemia. Immunol Genet J. 2019;2(3):124-134.
Aghamohammadi A, Allahverdi A, Abolhassani H, et al. Comparison of pulmonary diseases in common variable immunodeficiency and X-linked agammaglobulinaemia. Respirology. 2010;15(2):289-295.
Kainulainen L, Varpula M, Liippo K, Svedstrom E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104(5):1031-1036.
Moin M, Aghamohammadi A, Farhoudi A, et al. X-linked agammaglobulinemia: a survey of 33 Iranian patients. Immunol Invest. 2004;33(1):81-93.
Abolhassani H, Hirbod-Mobarakeh A, Shahinpour S, et al. Mortality and morbidity in patients with X-linked agammaglobulinaemia. Allergol Immunopathol. 2015;43(1):62-66.
Reisi M, Azizi G, Kiaee F, et al. Evaluation of pulmonary complications in patients with primary immunodeficiency disorders. Eur Ann Allergy Clin Immunol. 2017;49(3):122-128.
Azizi G, Abolhassani H, Hosein Asgardoon M, et al. The use of immunoglobulin therapy in primary immunodeficiency diseases. Endocr Metab Immune Disord Drug Targets. 2016;16(2):80-88.
Abolhassani H, Kiaee F, Tavakol M, et al. Fourth update on the Iranian National Registry of primary immunodeficiencies: integration of molecular diagnosis. J Clin Immunol. 2018;38(7):816-832.
Abolhassani H, Tavakol M, Chavoshzadeh Z, et al. National consensus on diagnosis and management guidelines for primary immunodeficiency. Immunol Genet J. 2019;2(1):1-21.
Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunol Pract. 2019;7(6):1763-1770.
Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
Abolhassani H, Chou J, Bainter W, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. J Allergy Clin Immunol. 2018;141(4):1450-1458.
Abolhassani H, Aghamohammadi A, Fang M, et al. Clinical implications of systematic phenotyping and exome sequencing in patients with primary antibody deficiency. Genet Med. 2019;21(1):243.
Standardization of spirometry-1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis. 1987;136(5):1285-1298.
Zapletal A, Samanek M, Paul T. Lung function in children and adolescents: methods, reference values. Progress in respiration research; 1987;22:83-112.
Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991;179(3):783-788.
van der Bruggen-Bogaarts BAHA, van der Bruggen HMJG, van Waes PFGM, Lammers J-W. Assessment of bronchiectasis: comparison of HRCT and spiral volumetric CT. J Comput Assist Tomogr. 1996;20(1):15-19.
Chen X-F, Wang W-F, Zhang Y-D, Zhao W, Wu J, Chen T-X. Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia: report from Shanghai, China (2000-2015). Medicine. 2016;95(32):2000-2015.
García-García E, Staines-Boone AT, Vargas-Hernández A, et al. Clinical and mutational features of X-linked agammaglobulinemia in Mexico. Clin Immunol. 2016;165:38-44.
Esenboga S, Cagdas D, Ozgur TT, et al. Clinical and genetic features of the patients with X-Linked agammaglobulinemia from Turkey: single-centre experience. Scand J Immunol. 2018;87(3):e12647.
Basile N, Danielian S, Oleastro M, et al. Clinical and molecular analysis of 49 patients with X-linked agammaglobulinemia from a single center in Argentina. J Clin Immunol. 2009;29(1):123-129.
Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine. 2006;85(4):193-202.
Pac M, Mikołuć B, Pietrucha B, et al. Clinical and immunological analysis of patients with X-linked agammaglobulinemia: single center experience. Centr Eur J Immunol. 2013;38:367-371.
Chun J-K, Lee TJ, Song JW, Linton JA, Kim DS. Analysis of clinical presentations of Bruton disease: a review of 20 years of accumulated data from pediatric patients at Severance Hospital. Yonsei Med J. 2008;49(1):28-36.
Pac MM, Bernatowska EA, Kierkuś J, et al. Gastrointestinal disorders next to respiratory infections as leading symptoms of X-linked agammaglobulinemia in children-34-year experience of a single center. Arch Med Sci. 2017;13(2):412.
Zhang Z-Y, Zhao X-D, Jiang L-P, et al. Clinical characteristics and molecular analysis of 21 Chinese children with congenital agammaglobulinemia. Scand J Immunol. 2010;72(5):454-459.
Eddens T, Kolls JK. Host defenses against bacterial lower respiratory tract infection. Curr Opin Immunol. 2012;24(4):424-430.
Xia S, Liu X, Cao X, Xu S. T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cell Mol Immunol. 2019.
Hurst JR, Workman S, Garcha DS, Seneviratne SL, Haddock JA, Grimbacher B. Activity, severity and impact of respiratory disease in primary antibody deficiency syndromes. J Clin Immunol. 2014;34(1):68-75.
Bierry G, Boileau J, Barnig C, et al. Thoracic manifestations of primary humoral immunodeficiency: a comprehensive review. Radiographics. 2009;29(7):1909-1920.
Bryan BA, Battersby A, Shillitoe BMJ, et al. Respiratory health and related quality of life in patients with congenital agammaglobulinemia in the northern region of the UK. J Clin Immunol. 2016;36(5):472-479.
Sweinberg SK, Wodell RA, Grodofsky MP, Greene JM, Conley ME. Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia. J Allergy Clin Immunol. 1991;88(1):96-104.
Rusconi F, Panisi C, Dellepiane R, et al. Pulmonary and sinus diseases in primary humoral immunodeficiencies with chronic productive cough. Arch Dis Child. 2003;88(12):1101-1105.
Lopez Granados E, Porpiglia AS, Hogan MB, et al. Clinical and molecular analysis of patients with defects in μ heavy chain gene. J Clin Investig. 2002;110(7):1029-1035.
Silva P, Justicia A, Regueiro A, Farina S, Couselo JM, Loidi L. Autosomal recessive agammaglobulinemia due to defect in mu heavy chain caused by a novel mutation in the IGHM gene. Genes Immun. 2017;18(3):197-199.
De Gracia J, Rodrigo MJ, Morell F, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med. 1996;153(2):650-655.
Pasteur M, Helliwell S, Houghton S, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4):1277-1284.
Quartier P, Debré M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134(5):589-596.
Liese JG, Wintergerst U, Tympner KD, Belohradsky BH. High-vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child. 1992;146(3):335-339.
Manson D, Reid B, Dalal I, Roifman CM. Clinical utility of high-resolution pulmonary computed tomography in children with antibody deficiency disorders. Pediatr Radiol. 1997;27(10):794-798.
Gharagozlou M, Ebrahimi FA, Farhoudi A, et al. Pulmonary complications in primary hypogammaglobulinemia: a survey by high resolution CT scan. Monaldi Arch Chest Dis. 2006;65(2):69-74.
Huo YK, Wang Z, Hong J-H, et al. Radiosensitivity of ataxia-telangiectasia, X-linked agammaglobulinemia, and related syndromes using a modified colony survival assay. Can Res. 1994;54(10):2544-2547.
Milito C, Pulvirenti F, Serra G, et al. Lung magnetic resonance imaging with diffusion weighted imaging provides regional structural as well as functional information without radiation exposure in primary antibody deficiencies. J Clin Immunol. 2015;35(5):491-500.

Auteurs

Saba Fekrvand (S)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Reza Yazdani (R)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Peter Olbrich (P)

Sección de Infectología e Inmunopatología, Unidad de Pediatría, Hospital Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain.

Gholamreza Azizi (G)

Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.

Rohola Shirzadi (R)

Department of Pediatric Pulmonary and Sleep Medicine, Children Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Mohammadreza Modaresi (M)

Department of Pediatric Pulmonary and Sleep Medicine, Children Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Mahsa Sohani (M)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Samaneh Delavari (S)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Arash Kalantari (A)

Department of Immunology and Allergy, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Mansoureh Shariat (M)

Department of Allergy and Clinical Immunology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Alireza Shafiei (A)

The Department of Immunology, Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Na Lu (N)

State Key Lab of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.

Gholamreza Hassanpour (G)

Center for Research of Endemic Parasites of Iran, Tehran University of Medical Sciences, Tehran, Iran.

Maziar Rahimi Hajiabadi (M)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Parisa Ashournia (P)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Anahita Razaghian (A)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Marzieh Asgharyan (M)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Zahra Shahraki-Ghadimi (Z)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Roja Rouhani (R)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Fatemeh Hoda Fallah (F)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Nima Rezaei (N)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.
Network for Immunology in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Hassan Abolhassani (H)

Research Center for Primary Immunodeficiencies, Iran University of Medical Sciences, Tehran, Iran.
Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at the Karolinska University Hospital Huddinge, Stockholm, Sweden.

Asghar Aghamohammadi (A)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH